Skip to main content


Page 1 of 3

  1. Acute ischemic stroke (Stroke) and transient ischemic attacks (TIA) are known complications in cancer patients and those with atrial fibrillation (AF). The role AF plays in Stroke/TIA in the setting of cancer ...

    Authors: Alia Khamis, Ala Emad Shaban, Tamer Salhab Altamimi, Zakaria Walid Shkoukani and Ismail Hamam
    Citation: Cardio-Oncology 2022 8:12
  2. Anthracycline chemotherapy and thoracic radiation therapy (RT) are known causes of cardiomyopathy among cancer survivors, however, management guidelines for this population are lacking. In this study we descri...

    Authors: Arash Delavar, Catherine Boutros, Dana Barnea, Wendy L. Schaffer MD and Emily S. Tonorezos
    Citation: Cardio-Oncology 2022 8:11
  3. During cancer treatment, patients have a significantly higher risk of developing cardiovascular complications such as hypertension. In this study, we investigated the internal relationships between hypertensio...

    Authors: Yanan Jiang, Chunpeng Shi, Songyu Tian, Fengnan Zhi, Xiuyun Shen, Desi Shang and Jinwei Tian
    Citation: Cardio-Oncology 2022 8:10
  4. Acute pericarditis is caused by the inflammation of the pericardium which can result in an effusion around the heart. Proton beam therapy causing radiation-induced pericarditis is not a well-known cause of per...

    Authors: Rahul Gupta, Muling Lin, Gary M. Freedman, Deborah W. Sundlof and Cheri Silverstein Fadlon
    Citation: Cardio-Oncology 2022 8:9
  5. Breast cancer survivors have reduced peak aerobic capacity (VO2peak) which may be related to latent or lingering chemotherapy induced cardiac damage. Nine, older (67 ± 3 years), long-term survivors (9.8 years) of...

    Authors: Rhys I. Beaudry, Mark J. Haykowsky, James P. MacNamara, Wesley J. Tucker, Roshni Rao, Barbara Haley and Satyam Sarma
    Citation: Cardio-Oncology 2022 8:8
  6. Anticancer therapy has the potential to cause unwanted cardiovascular side effects. Utilization of radiation therapy to treat tumors near the heart can result in radiation-induced valvular heart disease among ...

    Authors: Shivaraj Patil, Srinath-Reddi Pingle, Khalid Shalaby and Agnes S. Kim
    Citation: Cardio-Oncology 2022 8:7
  7. Chimeric antigen receptor T-cell (CART) therapy is a form of cellular immunotherapy used to treat hematologic malignancies. Major adverse cardiovascular events have been seen in CART patients who have high gra...

    Authors: Ashish Patel, Joshua Levenson, Ziyu Huang, Mounzer Agha and Kathleen Dorritie
    Citation: Cardio-Oncology 2022 8:6
  8. Programmed death-1 (PD-1) and programmed death- ligand 1 (PD-L1) inhibitors, such as pembrolizumab, nivolumab and atezolizumab, are major classes of immune checkpoint inhibitors that are increasingly used for ...

    Authors: Jiandong Zhou, Sharen Lee, Ishan Lakhani, Lei Yang, Tong Liu, Yuhui Zhang, Yunlong Xia, Wing Tak Wong, Kelvin King Hei Bao, Ian Chi Kei Wong, Gary Tse and Qingpeng Zhang
    Citation: Cardio-Oncology 2022 8:5
  9. Androgen deprivation therapy (ADT) and radiotherapy (RT) are the mainstay treatment for localized prostate cancer and recurrence after surgery. Cardiovascular (CV) toxicity of ADT is increasingly recognized, a...

    Authors: Youquan Li, Whee Sze Ong, Ma Than Than Shwe, Nelson Ling Fung Yit, Sheriff Zhan Hong Quek, Eric Pei Ping Pang, Wen Shen Looi, Wen Long Nei, Michael Lian Chek Wang, Melvin Lee Kiang Chua, Terence Wee Kiat Tan, Eu Tiong Chua, Choon Ta Ng and Jeffrey Kit Loong Tuan
    Citation: Cardio-Oncology 2022 8:4
  10. Checkpoint-inhibitor immunotherapies have had a profound effect in the treatment of cancer by inhibiting down-regulation of T-cell response to malignancy. The cardiotoxic potential of these agents was first de...

    Authors: Zachary L. Brumberger, Mary E. Branch, Max W Klein, Austin Seals, Michael D. Shapiro and Sujethra Vasu
    Citation: Cardio-Oncology 2022 8:3
  11. Cardiovascular diseases and cancer continue to be the two leading causes of death in the United States. While innovations in artificial intelligence, digital health, and telemedicine may revolutionize cardio-o...

    Authors: Sherry-Ann Brown, Craig Beavers, Hugo R. Martinez, Catherine H. Marshall, Iredia M. Olaye, Avirup Guha, David Cho, Alison Bailey, Carmen Bergom, Neha Bansal, Brenton Bauer and Richard K. Cheng
    Citation: Cardio-Oncology 2022 8:2
  12. Radiation-induced myocardial fibrosis increases heart failure (HF) risk and is associated with a restrictive cardiomyopathy phenotype. The myocardial extracellular volume fraction (ECVF) using contrast-enhance...

    Authors: Justin M. Canada, Elisabeth Weiss, John D. Grizzard, Cory R. Trankle, Leila Rezai Gharai, Franklin Dana, Leo F. Buckley, Salvatore Carbone, Dinesh Kadariya, Anthony Ricco, Jennifer H. Jordan, Ronald K. Evans, Ryan S. Garten, Benjamin W. Van Tassell, W. Gregory Hundley and Antonio Abbate
    Citation: Cardio-Oncology 2022 8:1
  13. Hematopoietic cell transplantation (HCT) is an established and potentially curative therapeutic option for hematologic cancers. HCT survivors are at risk of developing long-term complications impacting on morb...

    Authors: Alessandra Vecchié, Georgia Thomas, Edoardo Bressi, Aldo Bonaventura, Justin M. Canada, David Chuquin, Dinesh Kadariya, Usman Piracha, Delia Endicott, Roshanak Markley, Amir Toor, Michael Hess and Antonio Abbate
    Citation: Cardio-Oncology 2021 7:40
  14. All trans retinoic acid (ATRA) has revolutionized the treatment and outcomes of patients with Acute Promyelocytic Leukemia (APL). Induction therapy with ATRA is associated with the rare but potentially fatal c...

    Authors: Shabari Mangalore Shenoy, Thomas Di Vitantonio, Anna Plitt, Rocio Perez-Johnston, Jillian Gutierrez, David A. Knorr, Eytan M. Stein, Jennifer E. Liu and Stephanie Feldman
    Citation: Cardio-Oncology 2021 7:39
  15. Ibrutinib is a Bruton’s tyrosine kinase inhibitor used in the treatment of hematological malignancies. The most common cardiotoxicity associated with ibrutinib is atrial arrhythmia (atrial fibrillation and flu...

    Authors: Juan Carlo Avalon, Jacob Fuqua, Tyler Miller, Seth Deskins, Chelby Wakefield, Austin King, Sonya Inderbitzin-Brooks, Christopher Bianco, Lauren Veltri, Wei Fang, Michael Craig, Abraham Kanate, Kelly Ross, Midhun Malla and Brijesh Patel
    Citation: Cardio-Oncology 2021 7:38
  16. We have previously reported an increased risk for non-hematological malignancies in young patients with moderate or severe aortic stenosis (AS). These findings were the result of a post-hoc analysis from a lar...

    Authors: Walid Saliba, Tamir Bental, Yaron Shapira, Shmuel Schwartzenberg, Alex Sagie, Moti Vaturi, Salim Adawi, Alexander Fuks, Ami Aronheim and Avinoam Shiran
    Citation: Cardio-Oncology 2021 7:37
  17. Gilteritinib is a novel FMS-like tyrosine kinase 3 inhibitor recently approved by the United States Food and Drug Administration in 2018 for relapsed or refractory acute myeloid leukemia. However, gilteritinib...

    Authors: Lisa Kim, Brian Fowler, Courtney M. Campbell, Jeremy Slivnick, Haseeb Nawaz, Yaquta Kaka, Patrick Ruz, Ajay Vallakati, Ragavendra Baliga, Sumithira Vasu and Daniel Addison
    Citation: Cardio-Oncology 2021 7:36
  18. Sacubitril/valsartan has been shown to significantly reduce cardiovascular mortality and hospitalizations due to heart failure in patients with reduced ejection fraction (HFrEF) when compared to enalapril. Dat...

    Authors: Maria Klara Frey, Henrike Arfsten, Noemi Pavo, Emilie Han, Stefan Kastl, Martin Hülsmann, Mariann Gyöngyösi and Jutta Bergler-Klein
    Citation: Cardio-Oncology 2021 7:35
  19. Significantly increased risks of cardiovascular disease occur in testicular cancer survivors given cisplatin-based chemotherapy. The postulated mechanism of platinum-based chemotherapy’s vascular toxicity has ...

    Authors: Suparna C. Clasen, Paul C. Dinh Jr, Lifang Hou, Chunkit Fung, Howard D. Sesso and Lois B. Travis
    Citation: Cardio-Oncology 2021 7:34
  20. Recent advances in the treatment algorithms of early breast cancer have markedly improved overall survival. However, anthracycline- and trastuzumab-associated cardiotoxicity may lead to dose-reduction or halt ...

    Authors: A Mecinaj, G Gulati, SL Heck, E Holte, MW Fagerland, AI Larsen, E.S Blix, J Geisler, T Wethal and T Omland
    Citation: Cardio-Oncology 2021 7:33
  21. Cardiotoxicity resulting in heart failure (HF) is among the most dreaded complications of cancer therapy and can significantly impact morbidity and mortality. Leading professional societies in cardiology and o...

    Authors: Anecita P. Fadol, Ashley Patel, Valerie Shelton, Kate J. Krause, Eduardo Bruera and Nicolas L. Palaskas
    Citation: Cardio-Oncology 2021 7:32
  22. Nilotinib, a second-generation BCR-ABL tyrosine kinase inhibitor (TKI), is highly effective in the treatment of patients with chronic myeloid leukemia (CML), despite being more vasculotoxic than older TKIs suc...

    Authors: Shunsuke Maruta, Kyohei Usami, Kazuko Tajiri, Masafumi Otani, Daigo Hiraya, Hiroaki Watabe, Tomoya Hoshi, Akira Sato and Masaki Ieda
    Citation: Cardio-Oncology 2021 7:31
  23. While pre-existing cardiovascular disease (CVD) appears to be associated with poor outcomes in patients with Coronavirus Disease 2019 (COVID-19), data on patients with CVD and concomitant cancer is limited. Th...

    Authors: David M. Tehrani, Xiaoyan Wang, Asim M. Rafique, Salim S. Hayek, Joerg Herrmann, Tomas G. Neilan, Pooja Desai, Alicia Morgans, Juan Lopez-Mattei, Rushi V. Parikh and Eric H. Yang
    Citation: Cardio-Oncology 2021 7:28
  24. Immune checkpoint inhibitor (ICI) induced myocarditis is a rare, severe, and often fatal adverse event. Evidence to guide appropriate immunosuppressive therapy is scarce. We present a case of ICI-induced myoca...

    Authors: Emma Matzen, Lars Erik Bartels, Brian Løgstrup, Stine Horskær, Christina Stilling and Frede Donskov
    Citation: Cardio-Oncology 2021 7:27
  25. The emergence of immune checkpoint inhibitors (ICIs) has brought about a paradigm shift in cancer treatment as the use of these drugs has become more frequent and for a longer duration. As a result of T-cell-m...

    Authors: Shingo Kazama, Ryota Morimoto, Yuki Kimura, Naoki Shibata, Reina Ozaki, Takashi Araki, Takashi Mizutani, Hideo Oishi, Yoshihito Arao, Tasuku Kuwayama, Hiroaki Hiraiwa, Toru Kondo, Kenji Furusawa, Tomoya Shimokata, Takahiro Okumura, Yasuko K. Bando…
    Citation: Cardio-Oncology 2021 7:26
  26. Cardiovascular disease (CVD) and cancer are the top mortality causes globally, yet little is known about how the diagnosis of cancer affects treatment options in patients with hemodynamically compromising aort...

    Authors: Dominique J. Monlezun, Logan Hostetter, Prakash Balan, Nicolas Palaskas, Juan Lopez-Mattei, Mehmet Cilingiroglu, Zaza Iakobishvili, Michael Ewer, Konstantinos Marmagkiolis and Cezar Iliescu
    Citation: Cardio-Oncology 2021 7:25
  27. Increasing evidence suggests a multifaceted relationship exists between cancer and cardiovascular disease (CVD). Here, we introduce a 5-tier classification system to categorize cardio-oncology syndromes (COS) ...

    Authors: Rudolf A. de Boer, Joseph Pierre Aboumsallem, Valentina Bracun, Douglas Leedy, Richard Cheng, Sahishnu Patel, David Rayan, Svetlana Zaharova, Jennifer Rymer, Jennifer M. Kwan, Joshua Levenson, Claudio Ronco, Paaladinesh Thavendiranathan and Sherry-Ann Brown
    Citation: Cardio-Oncology 2021 7:24
  28. Cancer therapy-related cardiac dysfunction may occur in pediatric cancer survivors. Identification of early markers of myocardial damage secondary to anthracycline exposure is crucial to develop strategies tha...

    Authors: Cory V. Noel, Nino Rainusso, Matthew Robertson, Jonathan Romero, Prakash Masand, Cristian Coarfa and Robia Pautler
    Citation: Cardio-Oncology 2021 7:23
  29. Women with breast cancer (BCA) and cardiovascular disease (CVD) risk factors are at increased risk of developing cardiovascular complications when exposed to potentially cardiotoxic cancer therapy. The benefit...

    Authors: Michael G. Fradley, Mohammed Alomar, Marcus W. Kilpatrick, Bernadette Shields, Nhi Tran, Amey Best, Erika Bianco, Merna Armanious, R. Ashton Vautier, Kevin Kip, Theresa M. Beckie and Roohi Ismail-Khan
    Citation: Cardio-Oncology 2021 7:22
  30. Cardiac metastasis due to colon cancer is extraordinarily uncommon. Given the rarity of diagnosis, there is paucity of evidence and hence, no established guidelines for evaluation or clinical management strategy.

    Authors: Humaira Sarfraz, Abeer Arain, Mukul K. Divatia, Mary R. Schwartz and Kirk E. Heyne
    Citation: Cardio-Oncology 2021 7:21
  31. Cancer treatment-related morbidity relevantly compromises health status in cancer survivors, and efforts to optimise health-related outcomes in this population are vital to maximising healthy survivorship. A p...

    Authors: Renske Altena, Laila Hubbert, Narsis A. Kiani, Yvonne Wengström, Jonas Bergh and Elham Hedayati
    Citation: Cardio-Oncology 2021 7:20
  32. Modern therapies in oncology have increased cancer survivorship, as well as the incidence of cardiovascular adverse events. While immune checkpoint inhibitors have shown significant clinical impact in several ...

    Authors: Jessica Castrillon Lal, Sherry-Ann Brown, Patrick Collier and Feixiong Cheng
    Citation: Cardio-Oncology 2021 7:19
  33. Cancer patients with a history of radiotherapy are at an increased risk of ischemic heart disease. Preclinical animal studies demonstrate markedly impaired acetylcholine (ACh)-mediated endothelium-dependent va...

    Authors: Heather R. Banister, Stephen T. Hammond, Shannon K. Parr, Shelbi L. Sutterfield, Vanessa-Rose G. Turpin, Scott Treinen, Martin J. Bell and Carl J. Ade
    Citation: Cardio-Oncology 2021 7:18
  34. The CBR3 V244M single nucleotide polymorphism has been linked to the risk of anthracycline-related cardiomyopathy in survivors of childhood cancer. There have been limited prospective studies examining the impact...

    Authors: Jennifer K. Lang, Badri Karthikeyan, Adolfo Quiñones-Lombraña, Rachael Hageman Blair, Amy P. Early, Ellis G. Levine, Umesh C. Sharma, Javier G. Blanco and Tracey O’Connor
    Citation: Cardio-Oncology 2021 7:17
  35. Approximately 20% of cancer survivors treated with chemotherapy experience worsening heart failure (HF) symptoms post-cancer treatment. While research has predominantly investigated the role of cardiotoxic tre...

    Authors: Kerryn W. Reding, Nathaniel S. O’Connell, Ralph B. D’Agostino Jr, William Hundley, Alexander R. Lucas, Amy C. Ladd, Jennifer H. Jordan, Emily M. Heiston, Yaorong Ge and W. Gregory Hundley
    Citation: Cardio-Oncology 2021 7:16
  36. Breast cancer is the most common female cancer worldwide. Effective therapies including doxorubicin and trastuzumab have improved survival, but are associated with a substantial risk of cardiovascular disease....

    Authors: Rebecca K. Hoffman, Bang-Jin Kim, Payal D. Shah, Joseph Carver, Bonnie Ky and Sandra Ryeom
    Citation: Cardio-Oncology 2021 7:15
  37. The pathophysiology of hypertension and cancer are intertwined. Hypertension has been associated with an increased likelihood of developing certain cancers and with higher cancer-related mortality. Moreover, v...

    Authors: Turab Mohammed, Meghana Singh, John G. Tiu and Agnes S. Kim
    Citation: Cardio-Oncology 2021 7:14
  38. Glucocorticoid treatment remains the cornerstone of therapy for immune checkpoint inhibitor (ICI) myocarditis, but data supporting the use of additional immunotherapy for steroid refractory cases remains limit...

    Authors: Robert S. Zhang, Allison Padegimas, Kathleen M. Murphy, Peter T. Evans, Carli J. Peters, Christopher M. Domenico, Mahesh K. Vidula, Paul J. Mather, Marisa Cevasco, Roger B. Cohen, Joseph R. Carver and Rupal P. O’Quinn
    Citation: Cardio-Oncology 2021 7:13
  39. Trastuzumab reduces risk of breast cancer recurrence but carries risk of cardiotoxicity that may be reversible upon treatment cessation and institution of left ventricular (LV) enhancement therapies (LVETx). W...

    Authors: Ren Jie Robert Yao, Jordan Gibson, Christine Simmons and Margot K. Davis
    Citation: Cardio-Oncology 2021 7:12
  40. Immune checkpoint inhibitors (ICIs) are a novel class of anticancer agents that have demonstrated clinical response for both solid and hematological malignancies. ICIs are associated with development of immune...

    Authors: Nida Waheed, Michael G. Fradley, David L. DeRemer, Ahmad Mahmoud, Chintan P. Shah, Taimour Y. Langaee, Gloria P. Lipori, Keith March, Carl J. Pepine, Rhonda M. Cooper-DeHoff, Yonghui Wu and Yan Gong
    Citation: Cardio-Oncology 2021 7:10
  41. Due to advances in care, most women diagnosed with breast cancer do not die from the disease itself. Instead, cardiovascular disease (CVD) remains the most frequent cause of death. Many breast cancer patients ...

    Authors: Lisa Prior, Hannah Featherstone, David O’Reilly, Killian Nugent, Marvin Lim, John McCaffrey, Michaela J Higgins and Catherine M. Kelly
    Citation: Cardio-Oncology 2021 7:8
  42. Adjuvant systemic breast cancer treatment improves disease specific outcomes, but also presents with cardiac toxicity. In this post-hoc exploratory analysis of the OptiTrain trial, the effects of exercise on c...

    Authors: Josefin Ansund, Sara Mijwel, Kate A. Bolam, Renske Altena, Yvonne Wengström, Eric Rullman and Helene Rundqvist
    Citation: Cardio-Oncology 2021 7:7
  43. Cardiovascular toxicity is a notorious complication of doxorubicin (DXR) therapy for diffuse large B-cell lymphoma (DLBCL). Although surveillance of well-known biological markers for cardiovascular disease (CV...

    Authors: Charlott Mörth, Amal Abu Sabaa, Eva Freyhult, Christina Christersson, Jamileh Hashemi, Nashmil Hashemi, Masood Kamali-Moghaddam, Daniel Molin, Martin Höglund, Anna Eriksson and Gunilla Enblad
    Citation: Cardio-Oncology 2021 7:6
  44. Craniospinal irradiation (CSI) is part of the treatment of central nervous system (CNS) tumors and is associated with cardiovascular disease in adults. Global myocardial strain analysis including longitudinal ...

    Authors: Hugo R. Martinez, Ralph Salloum, Erin Wright, Lauren Bueche, Philip R. Khoury, Justin T. Tretter and Thomas D. Ryan
    Citation: Cardio-Oncology 2021 7:5
  45. Cancer therapy-related cardiac dysfunction (CTRD) is a major source of morbidity and mortality in long-term cancer survivors. Decreased GLS predicts decreased left ventricular ejection fraction (LVEF) in patie...

    Authors: Raquel Araujo-Gutierrez, Kalyan R. Chitturi, Jiaqiong Xu, Yuanchen Wang, Elizabeth Kinder, Alpana Senapati, L. Bindu Chebrolu, Mahwash Kassi and Barry H. Trachtenberg
    Citation: Cardio-Oncology 2021 7:4
  46. Cardiotoxicity remains a dreaded complication for patients undergoing chemotherapy with human epidermal growth factor (HER)-2 receptor antagonists and anthracyclines. Though many studies have looked at racial ...

    Authors: Crystal B. Chen, Raj K. Dalsania and Eman A. Hamad
    Citation: Cardio-Oncology 2021 7:3

Annual Journal Metrics

  • Speed
    46 days to first decision for all manuscripts
    37 days to first decision for reviewed manuscripts only
    74 days from submission to acceptance
    17 days from acceptance to publication

    128,227 Downloads (2021)
    280 Altmetric Mentions

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here